Protara Therapeutics (Nasdaq: TARA) posts 69% 6-month CR in TARA-002 BCG-naïve NMIBC trial - Stock Titan

Protara Therapeutics (Nasdaq: TARA) posts 69% 6-month CR in TARA-002 BCG-naïve NMIBC trial  Stock Titan